Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial

@inproceedings{Kuwabara2017IntravenousIF,
  title={Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial},
  author={Satoshi Kuwabara and Masahiro Mori and Sonoko Misawa and Miki Suzuki and Kazutoshi Nishiyama and Tatsuro Mutoh and Shizuki Doi and Norito Kokubun and Mikiko Kamijo and Hiroo Yoshikawa and Koji Abe and Yoshihiko Nishida and Kazumasa Okada and Kenji Sekiguchi and Ko Sakamoto and Susumu Kusunoki and Gen Sobue and Ryuji Kaji},
  booktitle={Journal of neurology, neurosurgery, and psychiatry},
  year={2017}
}
OBJECTIVE Short-term efficacy of induction therapy with intravenous immunoglobulin (Ig) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) is well established. However, data of previous studies on maintenance therapy were limited up to 24-week treatment period. We aimed to investigate the efficacy and safety of longer-term intravenous Ig therapy for 52 weeks. METHODS This study was an open-label phase 3 clinical trial conducted in 49 Japanese tertiary centres. 49… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 33 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-3 of 3 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Long - term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin : a retrospective study

Adrichem Me, F eftimov, IN vanSchaik
Muscle Nerve • 2013

efficacy and safety of in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

JM Léger, JL De Bleecker, C Sommer
J Peripher Nerv Syst 2013;18:130–40 • 2013

Similar Papers

Loading similar papers…